FDA Simplifies Rules for Foam Chemical Sterilants
Published Date: 6/26/2026
Rule
Summary
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Reclassified to Class II; Codified Rule
The FDA formally classified foam or gel chemical sterilants/high level disinfectants as Class II (special controls) and added the device type to 21 CFR 880.6886. This order is effective June 26, 2026 (classification applicable June 2, 2023), and lets these devices serve as predicates so future devices can use the less burdensome 510(k) pathway instead of automatic Class III review.
New Testing and Labeling Requirements
Manufacturers must meet specific special controls and remain subject to premarket notification (510(k)). Required controls include non-clinical performance testing (storage and transport stability, potency, simulated use and in-use testing), demonstrating at least a 1,000,000 (10^6) kill of the most resistant mycobacteria under labeled contact time, biocompatibility, human factors testing, chemical indicator validation, and detailed labeling (directions, PPE, disposal, storage/expiration, training statement, toxicology profile, and more).
Faster Access to Safer Disinfectants
Because FDA placed foam or gel chemical sterilants/high level disinfectants into Class II, patients and households may get safer, innovative cleaning products in hospitals and homes more quickly starting June 26, 2026. FDA says this classification will enhance patients' access by reducing regulatory burdens.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12953 — Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Previous / Next Documents
Previous: 2026-12898 — Air Plan Approval; District of Columbia; Creation of Synthetic Minor Permit Program
The EPA is giving a thumbs-up to DC’s new plan that creates a special permit program called the synthetic minor permit. This helps local businesses control pollution by setting clear, enforceable limits, making the air cleaner and rules easier to follow. The new rules kick in on July 27, 2026, and affect companies that release certain pollutants, helping DC meet clean air goals without extra costs.
Next: 2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.